

Трастузумаб
- английское имяTrastuzumab
- CAS №180288-69-1
- CBNumberCB61074602
- ФормулаC10H14N6O5
- мольный вес298.25536
- номер MDLMFCD03702625
- файл Mol180288-69-1.mol
химическое свойство
температура хранения | Store at -20°C |
форма | Solid |
цвет | White to light yellow |
Словарь онкологических терминов NCI | Herceptin |
FDA UNII | P188ANX8CK |
Словарь наркотиков NCI | Herceptin |
Банк данных об опасных веществах | 180288-69-1(Hazardous Substances Data) |
рисовальное письмо(GHS)
-
рисовальное письмо(GHS)
-
сигнальный язык
опасность
-
вредная бумага
H360:Может отрицательно повлиять на способность к деторождению или на неродившегося ребенка.
Трастузумаб химические свойства, назначение, производство
Использование
Trastuzumab is used to treat breast cancer. It is effective against tumors that overexpress the HER2/neu protien. As part of chemotherapy regimen for adjuvant treatment of lymph-node positive, HER2/neu positive cancer.Показания
The introduction of herceptin (Trastuzumab) into clinical practice for the treatment of breast cancer marks a major advance in the use of monoclonal antibody cancer therapy. Herceptin is a humanized antibody directed against the HER-2 antigen that is overexpressed on the tumor cell surface in approximately 25% of breast cancer patients. HER-2/neu/erbB2 overexpression marks an aggressive estrogen receptor–negative form of breast cancer. Therefore, a therapeutic agent selective for this target is particularly valuable. Herceptin is administered by intravenous infusion and in conjunction with paclitaxel can extend survival in patients with HER-2/neu/erbB2 overexpressing metastatic breast cancer.Herceptin use is associated with infusion- related hypotension, flushing and bronchoconstriction, and skin rash but no bone marrow toxicity. Herceptin appears to sensitize patients to cardiotoxicity, an important concern in patients also receiving doxorubicin.использованная литература
[1] Hamid Maadi. “Trastuzumab Mechanism of Action; 20 Years of Research to Unravel a Dilemma.” Cancers (2021).Трастузумаб поставщик
поставщик | телефон | страна | номенклатура продукции | благоприятные условия | |
---|---|---|---|---|---|
+8617315815539 | CHINA | 129 | 58 | ||
+86-0371-55170693 +86-19937530512 |
China | 21632 | 55 | ||
+86 18953170293 | China | 2930 | 58 | ||
0086-13720134139 | CHINA | 965 | 58 | ||
86-13657291602 | CHINA | 22963 | 58 | ||
+8618523575427 | China | 49732 | 58 | ||
+86-0371-86658258 +8613203830695 |
China | 29809 | 58 | ||
+1-781-999-5354 +1-00000000000 |
United States | 32161 | 58 | ||
+8613367258412 | China | 10319 | 58 | ||
86 18062405514 18062405514 |
CHINA | 3461 | 58 |